Brain-Computer Interface National Standard Approved, Synchron and Waveless Holographic Anticipate Deepening Industry Applications

In a significant move for the burgeoning field of brain-computer interfaces (BCIs), China’s National Technical Committee for Medical Appliances for Electro-Medical Equipment has initiated a public consultation phase for a new national standard focused on non-invasive medical devices utilizing BCI technology.

The proposed standard, titled “General Technical Conditions for Non-invasive Medical Devices Adopting Brain-Computer Interface Technology,” aims to establish crucial performance indicators and testing methodologies. It will cover aspects such as the acquisition and decoding of brain signals, the control of external devices, and the mechanical and usability aspects of wearable components that come into contact with the human body. This standard is designed to apply broadly to non-invasive medical devices that leverage BCI technology.

This regulatory development coincides with a major milestone in China’s BCI research. Recently, institutions including the Chinese Academy of Sciences’ Center for Excellence in Brain Science and Intelligence Technology successfully conducted China’s first prospective clinical trial for an invasive BCI. This achievement positions China as the second country globally to reach the clinical trial phase for invasive BCI technologies.

The BCI market is experiencing robust growth, propelled by groundbreaking advancements that promise to revolutionize healthcare. From a technological standpoint, BCIs hold immense potential to restore communication channels for patients with severe disabilities and to aid individuals with paralysis in regaining motor function. Beyond therapeutic applications, BCI research is also exploring cognitive enhancements, aiming to improve learning efficiency, memory retention, and to pioneer novel human-computer interaction paradigms.

BCI technology is rapidly transitioning from the confines of research laboratories to becoming scalable, practical solutions. Industry projections suggest that widespread commercialization in the medical sector could occur within the next five years, with various BCI approaches already in or entering clinical trials. Notably, disruptive progress from Elon Musk’s Neuralink is accelerating, with expectations of a doubling in clinical trial patient numbers within a year.

In parallel, Synchron, a key competitor to Neuralink in the BCI space, is advancing its innovative endovascular approach. This minimally invasive technique allows for the delivery of electrodes to the blood vessels of the brain’s motor cortex, facilitating the precise collection of brain electrical signals.

Synchron highlights its pioneering role, having been the first BCI company to commence clinical trials for implantable systems in 2019. A significant breakthrough occurred in September 2024, when a patient with amyotrophic lateral sclerosis (ALS) successfully controlled smart home devices by using their thoughts to operate the “Tap to Alexa” accessibility feature on an Amazon Kindle Fire tablet.

Industry analysts are bullish on the market’s trajectory. Zhongtai Securities, citing projections from Precedence Research, anticipates a substantial market expansion of approximately $10 billion over the next decade. Kaiyuan Securities notes the accelerating development of BCIs, with leading domestic and international companies in product registration or clinical research phases, indicating a promising future. Founder Securities posits that BCIs are poised to become the cornerstone of next-generation human-computer interaction, fundamentally reshaping how humans engage with technology.

Micro-vision Holography Deepens Application Scenarios

Micro-vision Holography has been strategically expanding its footprint in the BCI sector in recent years. Through dedicated research and development, and the cultivation of an robust industrial ecosystem, the company has filed hundreds of patents in core areas such as “holographic brain-controlled robot systems” and “brain-computer interface signal processing methods.” These patents span hardware design, data processing, and human-computer interaction technologies, underscoring the company’s forward-thinking strategy and innovative drive.

Furthermore, Micro-vision Holography is actively constructing an integrated ecosystem encompassing “Brain-Computer Interface + Humanoid Robots + Quantum Computing.” By achieving technological breakthroughs, implementing practical use cases, and fostering ecosystem integration, the company is exploring diverse applications across human-computer interaction, industrial safety, and smart living. This multifaceted approach is accelerating the transition of BCI technology from laboratory research to industrial application, providing foundational technological support for the future of human-computer interaction and aiming to secure a central position in the burgeoning multi-billion dollar BCI market.

Conclusion

Driven by a dual engine of technological breakthroughs and clinical validation, the brain-computer interface industry is approaching a pivotal inflection point for commercialization. With strengthening expectations for industrial adoption, BCIs are poised to enter a phase of rapid growth. In the medium term, output-oriented BCI technologies are expected to expand into education, entertainment, military, and industrial sectors. In the long term, BCI technology will evolve towards functional enhancement and augmentation, ultimately realizing integrated brain-machine intelligence.